Navigation Links
Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Date:2/5/2008

For a more detailed discussion of forward looking statements, please see additional information below.

With respect to 2008, sales are projected to be in the range of $255 million to $265 million, with an expectation that the HeartMate II will launch at the end of the 1st quarter.

Cardiovascular Division growth is expected to be from the low to mid teens, with growth primarily based upon the launch of HeartMate II in the U.S. including its introduction to a broader set of transplant centers, growth in implant volumes at existing trial centers and an increase in the HeartMate II average selling price. Continued growth is also expected in Europe.

We expect that ITC will grow in the mid-single digits, with growth coming from our Hospital Point of Care and Alternate Site products.

GAAP gross margins are expected to be between 58% and 59%, with non-GAAP gross margins between 59% and 60%.

GAAP income from operations is expected to increase between 150% and 300% over 2007, while non-GAAP income from operations is expected to increase between 15% and 30%. The increase reflects leverage in the business, while continuing investments in product development, market development and HeartMate II launch activities.

Weighted average shares outstanding are expected to be between 56 million and 57 million for GAAP and 63 million and 64 million shares for non-GAAP. We expect our convertible debt to continue to be dilutive in 2008 for non-GAAP EPS. The increase in share count is expected to be partially offset by adding back the interest expense on the notes.

GAAP EPS is expected to be between $0.09 to $0.12, while non-GAAP EPS will be in a range of $0.36 to $0.40.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by its products and certain costs of producing that revenue, such as costs of product sale
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Thoratec Presentation at JP Morgan Conference to be Webcast
2. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
3. Thoratec Presentation at Bear Stearns Conference To Be Webcast
4. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
9. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
(Date:7/28/2014)... July 28, 2014 /PRNewswire/ -   JOLT , a ... companies to join its growing portfolio of startups. Next-level ... Toronto,s JOLT accelerator, and Cohort four ... roster. Since its launch in July ... raised  $7.5M of financing. Now at 23 investments, JOLT,s ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... BRISBANE, Calif. , May 4 InterMune, Inc. (Nasdaq: ... issued a complete response letter for the New Drug Application (NDA) for ... to reduce decline in lung function. , ... A complete response letter is issued by the FDA,s Center ...
... Calif. , May 4 S*BIO Pte Ltd and Onyx ... development collaboration and option and license commercialization agreement for S*BIO,s novel JAK2 ... respectively. The expanded agreement builds upon the development and commercialization collaboration between ... , , ...
... Fla. , May 4 Romark Laboratories announced results ... of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. ... a late breaking forum of the American Gastroenterological Association Institute (AGA ... . , , , ...
Cached Biology Technology:InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/27/2014)... scientists have identified more than two dozen genetic ... that had not been previously reported. The study, ... funded by the National Institutes of Health (NIH) ... , "Unraveling the genetic underpinnings of Parkinson,s is ... this complex disease, and hopefully, may one day ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
Breaking Biology News(10 mins):Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... A research team, led by Institute of Zoology ... reconstructed a continuous population history of the giant panda ... whereas global changes in climate were the primary drivers ... activities were likely to underlie recent population divergence and ...
... the IOF Regionals Asia-Pacific Osteoporosis Meeting, researchers from the ... Health, announced a study which links carotenoids to decreased ... who are lean (BMI In the study, ... and hip fracture risk across a range of BMI ...
... to crizotinib gaining approval for the treatment of advanced ... the United States, Canada, and several other countries in ... therapy for ALK-positive NSCLC places great emphasis on rapid, ... subtype of lung cancer. A recent study published in ...
Cached Biology News:Chinese scientists discover evidence of giant panda's population history and local adaptation 2Chinese scientists discover evidence of giant panda's population history and local adaptation 3Study shows immunohistochemistry is reliable screening tool for ALK rearrangement 2
Request Info...
Request Info...
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
Biology Products: